| Excerpt | Reference |
|---|
| "Recently, differentiation therapy of acute promyelocytic leukemias (AML3 subtype) with all-trans-retinoic acid has been shown to be an efficient alternative to chemotherapy." | ( Balitrand, N; Chomienne, C; Cornic, M; Degos, L; Delva, L; Guidez, F, 1992) |
| "On a diagnosis of acute promyelocytic leukemia and treated with induction chemotherapy consisting of behenoyl-arabinofuranosyl cytosine (BHAC), daunorubicin, 6-mercaptopurine (6-MP) and prednisolone (PSL) was reformed." | ( Ashihara, E; Fujita, N; Gotoh, H; Inaba, T; Itoh, K; Murakami, S; Nishio, A; Ohkawa, K; Oku, N; Shimazaki, C, 1992) |
| "Retinoic acid therapy for acute promyelocytic leukemia represents a unique example where a molecular defect may be involved both in the pathogenesis and treatment of a malignancy." | ( Dmitrovsky, E; Frankel, SR; Miller, WH, 1992) |
| "Seven patients with acute promyelocytic leukemia (APL) were treated with all-trans retinoic acid (ATRA)." | ( Carnot, J; Dorticós, E; Espinosa, E; González, A; Hernández, P; Rodríguez, I, 1992) |
| "We report a case of an acute promyelocytic leukemia patient who showed remarkable thrombopoiesis prior to granulopoiesis by human macrophage colony-stimulating factor (hM-CSF) treatment after chemotherapy." | ( Akiyoshi, T; Hisano, S; Ishibashi, M; Kimura, N; Morioka, E; Okumura, M; Suzumiya, J; Uchida, T, 1992) |
| "A 41-year-old man with untreated acute promyelocytic leukemia (APL) was treated with all-trans retinoic acid (ATRA) 80mg/body/day per os." | ( Deguchi, K; Kihira, H; Kita, K; Kobayashi, T; Mahmud, N; Shirakawa, S; Takahashi, T; Taniguchi, M; Tsukada, T, 1992) |
| "A 14-year-old girl with acute promyelocytic leukemia (APL) developed cardiomyopathy following chemotherapy for remission induction and subsequent consolidation consisting of cumulative doses of 644 mg/m2 of daunorubicin and 31 mg/m2 of mitoxantrone." | ( Azuno, Y; Hiroshige, Y; Nishimura, M; Nishimura, Y; Okafuji, K; Seguchi, M; Tanaka, H; Tanaka, M; Ueda, K; Yoshida, T, 1992) |
| "We described two pediatric patients with acute promyelocytic leukemia (APL) who were successfully induced into complete remission with all-trans retinoic acid (ATRA, 45 mg/m2 per day) after failing on conventional chemotherapy." | ( Fujimoto, T; Kawai, S; Kitano, Y; Konno, K; Min, ZZ; Sakakibara, Y; Shimizu, H, 1992) |
| "A patient with resistant acute promyelocytic leukemia was treated with all-trans-retinoic acid (45 mg/m2 per day for 42 days) and obtained complete remission at day 14." | ( Furuya, T; Itoh, Y; Kuratsuji, T; Ohno, R; Ohtaka, M; Ohyashiki, K; Toyama, K, 1992) |
| "It has been shown that patients with acute promyelocytic leukemia (AML3 subtype) treated with all-trans retinoic acid (all-trans RA), 45 mg/m2/day, achieve complete remission through differentiation of the leukemic clone to mature myeloid cells, which die spontaneously." | ( Agadir, A; Castaigne, S; Chomienne, C; Degos, L; Dreux, C; Gourmel, B; Lefebvre, P; Thomas, G, 1991) |
| "Thirty-nine patients with untreated acute promyelocytic leukemia (APL) were randomly allocated to receive rubidazone (zorubicin) 200 mg/m2/d, days 1 to 4 plus cytarabine (Ara C) 200 mg/m2/d, days 1 to 7 (arm A, 21 patients), or amsacrine (Amsa) 150 mg/m2/d, days 1 to 4 plus Ara C 200 mg/m2/d, days 1 to 7 (arm B, 18 patients)." | ( Bordessoule, D; Castaigne, S; Colombat, P; Fenaux, P; Guy, H; Le Gall, E; Leblay, R; Leverger, G; Tertian, G; Tilly, H, 1991) |
| "The advent of retinoic acid (RA) in the treatment of acute promyelocytic leukemia (APL) has led to a high frequency of short-lasting complete remissions (CR)." | ( Alcalay, M; Avvisati, G; Biondi, A; Diverio, D; Lo Coco, F; Moleti, ML; Pandolfi, PP; Petti, MC; Rambaldi, A; Zangrilli, D, 1991) |
| "Eleven patients with acute promyelocytic leukemia were treated with tretinoin administered orally at a dose of 45 mg per square meter of body-surface area per day." | ( Andreeff, M; Frankel, SR; Hittelman, WN; Itri, LM; Jakubowski, A; Miller, WH; Scheinberg, DA; Tafuri, A; Vyas, R; Warrell, RP, 1991) |
| "Fifty patients with acute promyelocytic leukemia (APL) have been treated with all-trans retinoic acid (RA)." | ( Chen, ZX; Li, C; Ling, BJ; Tao, RF; Wang, W; Xia, XM; Xue, YQ; Yao, XZ; Zhang, R; Zu, WY, 1991) |
| "Twenty-two patients with acute promyelocytic leukemia were treated with all-trans retinoic acid (RA, 45 mg/m2 per day) for 90 days." | ( Ballerini, P; Berger, R; Castaigne, S; Chomienne, C; Daniel, MT; Degos, L; Fenaux, P, 1990) |
| "A 36-year-old male with acute promyelocytic leukemia in second relapse was admitted to receive reinduction therapy in June, 1985, and entered into third complete remission, but he developed spiky fever after chemotherapy." | ( Aotsuka, N; Asai, T; Endoh, N; Hirasawa, A; Hiruma, K; Ishii, H; Morio, S; Oh, H; Wakita, H; Yoshida, S, 1990) |
| "A 67-year-old woman with acute promyelocytic leukemia (APL) showed a marked decrease in leukemic promyelocytes with concomitant maturation of leukemic cells during treatment with retinol palmitate." | ( Iwasaki, H; Kawai, Y; Nakamura, T; Tanaka, T; Tsutani, H; Uchida, M; Ueda, T, 1990) |
| "A patient diagnose of acute promyelocytic leukemia treated with chemotherapy schedule type VAPA." | ( del Potro Gómez, E; Díaz Mediavilla, J; Díaz Morfa, M; Espinos Pérez, D; López Martín, JC; Martínez Martínez, R, 1989) |
| "Fifty-seven adult patients with acute promyelocytic leukemia (APL) were treated between 1974 and 1984 with daunorubicin (DNR) or 4-(9-acridinylamino)methanesulfan-m-anisidide (AMSA) in combination with arabinosylcytosine (Ara-C) and 6-thioguanine (TG); they also received prophylactic heparin." | ( Clarkson, BD; Cunningham, I; Gee, TS; Kempin, SJ; Naval, AN; Reich, LM, 1989) |
| "He was diagnosed as having acute promyelocytic leukemia, and he was treated with the BHAC-DMP protocol." | ( Furuya, H; Ichiba, S; Kato, Y; Takagi, C; Wakayama, T, 1994) |
| "The mechanisms underlying acute promyelocytic leukemia (APL) coagulopathy and its reversal by administration of all-trans retinoic acid (ATRA) have been investigated." | ( d'Onofrio, G; De Stefano, V; Di Mario, A; Leone, G; Mastrangelo, S; Rumi, C; Rutella, S; Salutari, P; Sica, S; Teofili, L, 1995) |
| "Treatment of acute promyelocytic leukemia (APL) blasts with cyclic adenosine monophosphate (cAMP) analogs, in combination with all-trans retinoic acid (ATRA), results in the upregulation of the expression of leukocyte alkaline phosphatase (LAP), a marker for the differentiation of the granulocyte." | ( Barbui, T; Garattini, E; Gianní, M; Norio, P; Rambaldi, A; Terao, M, 1995) |
| "The current treatment of acute promyelocytic leukemia (APL, also called AML3 subtype) is focused on differentiating agents such as the vitamin A derivative all-trans retinoic acid (ATRA)." | ( Balitrand, N; Castaigne, S; Chomienne, C; Cornic, M; Degos, L; Delva, L; Lefebvre, P, 1994) |
| "The major cause of early death in acute promyelocytic leukemia (APL), the high risk of a bleeding diathesis is now successfully counteracted within a few days by differentiation therapy using ATRA." | ( Degos, L, 1994) |
| "A 61-year-old man with acute promyelocytic leukemia (APL) is described in whom some leukemic promyelocytes contained granules similar to those of basophils, and hyperhistaminemia developed after treatment with all-trans retinoic acid." | ( Kuriyama, K; Shimamoto, Y; Suga, K; Tomonaga, M; Yamaguchi, M, 1994) |
| "Chemotherapy may decrease relapses of acute promyelocytic leukemia (APL) following induction with all-trans retinoic acid (ATRA), however the optimal timing of these two modalities remains to be determined." | ( Ahmed, T; Arlin, Z; Feldman, EJ; Miller, WH; Seiter, K, 1995) |
| "In t(15;17) acute promyelocytic leukemia, all-trans retinoic acid (RA) induces leukemic cell maturation in vitro and remission in acute promyelocytic leukemia patients, but in vivo treatments invariably lead to relapse with resistance to RA." | ( Doskeland, SO; Duprez, E; Gendron, MC; Genieser, HG; Houge, G; Jastorff, B; Lanotte, M; Ruchaud, S, 1994) |
| "Patients with acute promyelocytic leukemia (APL) associated with the t(15;17) translocation and fusion of the promyelocytic leukemia (PML) and retinoic acid receptor-alpha (RAR-alpha) genes achieve complete remission but not cure with all-trans retinoic acid (RA), NB4, a cell line derived from a patient with t(15;17) APL that undergoes granulocytic differentiation when treated with pharmacologic doses of RA, was used as a model for differentiation therapy of APL." | ( Chen, A; Hellinger, N; Licht, JD; Scher, W; Waxman, S; Wu, Y, 1994) |
| "A large number of acute promyelocytic leukemia (APL) patients, treated with all-trans retinoic acid (ATRA) and chemotherapy, were studied." | ( Chen, SJ; Chen, Z; Gu, LJ; Huang, LA; Huang, W; Li, XS; Lu, JX; Ouyang, RR; Wang, ZY; Zhang, FQ, 1993) |
| "The patient was diagnosed as having acute promyelocytic leukemia (APL) and started to receive treatment with all-trans retinoic acid (ATRA) 70 mg/body/day per os." | ( Doi, H; Inada, T; Shirono, K; Tsuda, H, 1994) |
| "She was diagnosed as having acute promyelocytic leukemia (APL), and treatment with daily oral administration of all-trans retinoic acid (ATRA) (70 mg/body/day) was begun." | ( Ikeda, Y; Iki, S; Ohbayashi, Y; Urabe, A; Yoshinaga, K, 1994) |
| "Treatment of acute promyelocytic leukemia (APL) patients with all-trans retinoic acid (ATRA) was associated with rapid improvement in hemostatic markers." | ( Kamata, T; Kawai, Y; Kizaki, M; Moriki, T; Murata, M; Nakajima, H; Tokuhira, M; Uchida, H; Watanabe, K; Yokoyama, K, 1994) |
| "The major cause of early death in acute promyelocytic leukemia (APL), the high risk of a bleeding diathesis is now successfully counteracted within a few days by differentiation therapy using ATRA." | ( Degos, L, 1994) |
| "The current treatment of acute promyelocytic leukemia (APL, also called AML3 subtype) is focused on differentiating agents such as the vitamin A derivative all-trans retinoic acid (ATRA)." | ( Balitrand, N; Castaigne, S; Chomienne, C; Cornic, M; Degos, L; Delva, L; Lefebvre, P, 1994) |
| "A case of 62-year-old female with acute promyelocytic leukemia is presented, in whom in poor general condition, and with symptoms of severe haemorrhagic diathesis and biochemical signs of coagulopathy a treatment with trans-retinoic acid was induced." | ( Nowak, WS; Sacha, T; Skotnicki, AB; Stoch, A, 1994) |
| "Patients with acute promyelocytic leukemia (APL) are at high risk for the development of life-threatening thrombotic and hemorrhagic complications, particularly during induction chemotherapy." | ( Hakimian, D; Kwaan, HC; Rickles, FR; Tallman, MS, 1993) |
| "A 46-year-old woman with acute promyelocytic leukemia (APL) was treated with all-trans retinoic acid (ATRA) and chemotherapy according to the AML-92, M3 regimen of the Japan Adult Leukemia Study Group (JALSG)." | ( Kanbayashi, H; Maruyama, Y; Matsuda, S; Ohno, R; Saitoh, Y; Sakuma, H; Tanaka, T, 1993) |
| "Two cases of acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) developed fever, dyspnea and chest pain." | ( Aiso, M; Horie, T; Horikoshi, A; Iizuka, Y; Kawamura, M; Naoe, T; Ohno, R; Ohshima, T; Sawada, S; Takeuchi, J, 1993) |
| "We treated 70 acute promyelocytic leukemia (APL) patients with daily oral 45 mg/m2 all-trans-retinoic acid (ATRA) in two multi-institutional prospective studies." | ( Endoh, N; Fujimoto, T; Fukutani, H; Hiraoka, A; Kobayashi, T; Kyo, T; Naoe, T; Ohno, R; Ohshima, T; Yoshida, H, 1993) |
| "18 patients with acute promyelocytic leukemia (APL) were treated with HATP (Harringtonine, Adriamycin, Thioguanine, Prednisone) chemotherapy combined with chinese traditional medications." | ( Guo, AX; Huang, SL; Wang, QE, 1993) |
| "All trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia is the first model of differentiation therapy in malignancies, and represents the first strict correlation between a genetic defect and a specific treatment." | ( Degos, L, 1993) |
| "We treated 70 patients with acute promyelocytic leukemia (APL) with daily oral 45 mg/m2 all-trans retinoic acid (ATRA) in 2 multi-institutional prospective studies." | ( Fukutani, H; Naoe, T; Ohno, R, 1993) |
| "We treated 70 patients with acute promyelocytic leukemia (APL) with daily oral 45 mg/m2 all-trans retinoic acid (ATRA) in 2 multi-institutional prospective studies." | ( Ohno, R, 1993) |
| "To discuss acute promyelocytic leukemia (APL) and review the literature concerning differentiation treatment of APL with trans-retinoic acid (t-RA)." | ( Dulaney, AM; Murgatroyd, RJ, 1993) |
| "We report a young woman with acute promyelocytic leukemia who showed primary resistance to chemotherapy and who responded to ATRA treatment." | ( Berlanga, JJ; Ferra, C; Gallardo, D; Grañena, A; Querol, S, 1995) |
| "The response of acute promyelocytic leukemia (APL) peripheral blood and bone marrow cells to trans-retinoic acid (RA) was cytogenetically characterized during RA treatment using the techniques of premature chromosome condensation (PCC) and fluorescence in situ hybridization (FISH)." | ( Agbor, P; Frankel, SR; Hittelman, WN; Miller, WH; Vyas, RC; Warrell, RP, 1996) |
| "The cells from patients with acute promyelocytic leukemia (AML M3) undergo terminal differentiation when treated with all-trans retinoic acid (ATRA)." | ( Balitrand, N; Chomienne, C; Degos, L; Delva, L; Dombret, H; Paul, P; Renesto, P; Scrobohaci, ML; Seale, J, 1996) |
| "A 53-year-old man with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) developed fever and small erythemas on his arms and legs when the peripheral blood neutrophil count had increased." | ( Kiyofuji, C; Shirono, K; Tsuda, H, 1995) |
| "Treatment of acute promyelocytic leukemia (APL) by all-trans retinoic acid (ATRA) is the first model of differentiation therapy allowing achievement of more than 90% complete remission (CR)." | ( Balitrand, N; Barbey, S; Calabresse, C; Chomienne, C; Degos, L; Fenaux, P; Venturini, L, 1995) |
| "Ten patients with acute promyelocytic leukemia (APL) were treated with all-trans retinoic acid (ATRA)." | ( Aoki, S; Hashimoto, S; Kishi, K; Koike, T; Shibata, A; Takahashi, H; Takahashi, M; Tsukada, N; Wada, K, 1996) |
| "A case of acute promyelocytic leukemia (APL) complicated by sinus bradyarrhythmia during the course of all-trans retinoic acid (ATRA) administration is reported." | ( Koizumi, S; Maruhashi, K; Taniguchi, M; Wada, H, 1996) |
| "Ten year old boy with acute promyelocytic leukemia (APL) was treated with all-trans retinoic acid (ATRA)." | ( Abe, T; Hata, M; Hattori, T; Iinuma, H; Ito, T; Kamakura, M; Nakayama, T; Okano, S; Okinaga, K; Yasuda, K, 1996) |
| "Treatment of two acute promyelocytic leukemia patients with ATRA induced maximal 2." | ( Azuma, H; Kanagawa, Y; Mima, N; Miyamoto, K; Saito, S; Shigekiyo, T; Shirakawa, M; Watanabe, A; Yamaguchi, H, 1996) |
| "We have treated 2 patients with acute promyelocytic leukemia intubated due to massive alveolar bleeding in this manner, and have observed a differentiation of promyelocytes to granulocytes and complete remission in both patients, indicating that the ATRA administered had been resorbed intestinally." | ( Bargetzi, MJ; Gratwohl, A; Speck, B; Tichelli, A, 1996) |
| "We treated two children with acute promyelocytic leukemia (APL) in whom complete remission was successfully induced by oral administration of all-trans retinoic acid (ATRA)." | ( Hatae, Y; Iizuka, S; Imaizumi, M; Nakadate, H; Shikano, T; Takeda, T, 1996) |
| "We describe a patient with acute promyelocytic leukemia (APL) who was successfully induced into remission with all-trans retinoic acid (ATRA) and idarubicin, but developed myelodysplastic syndrome (MDS) with monosomy 7 shortly after conclusion of maintenance therapy with idarubicin alternating with 6-mercaptopurine, vincristine, methotrexate and prednisone." | ( Bseiso, AW; Estey, E; Kantarjian, H, 1997) |
| "Patients with acute promyelocytic leukemia (APL) usually relapse after all-trans retinoic acid (RA) treatment because this therapy fails to eradicate the malignant clone." | ( Binderup, L; Elstner, E; Koeffler, HP; Le, J; Linker-Israeli, M; Michl, P; Reed, JC; Said, JW; Umiel, T, 1997) |
| "Treatment of freshly isolated acute promyelocytic leukemia (APL) cells and the myelogenous leukemia cell lines, NB4, HL-60, and U937, with all-trans retinoic acid (ATRA) results in a remarkable elevation in the amounts of Stat1 alpha and Stat2 proteins." | ( Barbui, T; Fortino, I; Garattini, E; Gianni, M; LiCalzi, M; Rambaldi, A; Terao, M; Viggiano, V, 1997) |
| "A 29-year-old woman with acute promyelocytic leukemia and DIC at 24 weeks' gestation was treated successfully with all-trans retinoic acid during the pregnancy, delivering a viable, normal infant at 33 weeks." | ( Byrne, JD; Incerpi, MH; Miller, DA; Posen, R, 1997) |
| "We treated 2 patients with refractory acute promyelocytic leukemia (APL) in a pilot study of ATRA followed by intensive chemotherapy (APL-ATRA protocol)." | ( Fujimoto, T; Hirota, T; Katano, N; Konno, K; Miyake, M; Sakakibara, Y; Takitani, K; Tsurusawa, M, 1997) |
| "A 10-year-old boy with acute promyelocytic leukemia (APL) was treated with all-trans-retinoic acid (ATRA) at a dose of 60 mg/m2/day." | ( Hernández, P; Martínez, G; Menéndez, A; Svarch, E, 1998) |
| "Typical acute promyelocytic leukemia (APL) is associated with expression of the PML-RARalpha fusion protein and responsiveness to treatment with all-trans retinoic acid (ATRA)." | ( Guidez, F; Ivins, S; Söderström, M; Waxman, S; Zelent, A; Zhu, J, 1998) |
| "In the present study, the acute promyelocytic leukemia cell line (NB4) was found to undergo monocyte/macrophage differentiation and strongly express ALP activity after exposure to the combination of 1alpha,25(OH)2D3 and PMA treatment." | ( Norman, AW; Song, X, 1998) |
| "In contrast, acute promyelocytic leukemia (APL) cells showed synergistic differentiation after treatment with all-trans retinoic acid (RA) and bufalin." | ( Hino, K; Honma, Y; Tomoyasu, S; Tsuruoka, N; Yamada, K, 1998) |
| "This study evaluated whether relapse of acute promyelocytic leukemia (APL) patients from clinical remissions achieved and/or maintained with all-trans retinoic acid (RA) in combination with intensive chemotherapy is associated with leukemic cellular resistance to RA and with alterations in the PML-RARalpha fusion gene." | ( Carrera, I; Ding, W; Gallagher, RE; Grills, G; Li, YP; Nobile, LM; Paietta, E; Tallman, MS; Wiernik, PH, 1998) |
| "A 46 year old male with acute promyelocytic leukemia treated with all-trans retinoic acid (ATRA), developed fever, bilateral erythematous nodules in his axillary area, lower abdomen and inguinal region." | ( Arun, B; Azumi, N; Berberian, B; Frankel, SR; Freter, C; Luksenburg, H, 1998) |
| "Thirty-seven patients with acute promyelocytic leukemia (APL) were treated with all-trans retinoic acid (ATRA)." | ( de-Medeiros, BC; de-Medeiros, CR; Pasquini, R; Strapasson, E, 1998) |
| "Seventy-two patients with acute promyelocytic leukemia (APML) were treated at St." | ( Amess, J; Carter, M; Howe, K; Lister, TA; Rohatiner, AZ; Slater, S, 1999) |
| "In two patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) in combination with chemotherapy, we demonstrated that cells with apoptotic morphology were recognized in a small fraction of whole blood cells (0." | ( Hayashi, Y; Iinuma, K; Imaizumi, M; Saito, T; Sato, A; Suzuki, H; Yoshinari, M, 1999) |
| "Fifty-eight acute promyelocytic leukemia (APL) patients (11 newly diagnosed and 47 relapsed) were studied for arsenic trioxide (As2O3) treatment." | ( Cao, Q; Chen, GQ; Chen, SJ; Chen, Y; Chen, Z; Gu, BW; Gu, FY; Hu, J; Li, JM; Li, XS; Liu, JX; Niu, C; Ren, MY; Shen, ZX; Su, XY; Sun, HP; Wang, ZY; Waxman, S; Wu, W; Xiong, SM; Yan, H; Yang, RR; Yu, T; Yuan, MM; Zeng, XY; Zhang, FQ; Zhang, TD; Zhou, L, 1999) |
| "1 patient had pretreated acute promyelocytic leukemia." | ( Ataullakhanov, FI; Garmaeva, TTs; Isaev, VG; Kucher, RA; Parovichnikova, EN; Savchenko, VG; Skorokhod, AA; Tiurina, NG; Vitvitskiĭ, VM, 1999) |
| "We describe two additional patients with acute promyelocytic leukemia who had unexplained fever and myalgias (cutaneous lesions in one patient) during induction therapy with ATRA." | ( Crader, SC; Hogan, MC; Letendre, L; Morales, CE; Pruthi, RK; Roberson, AE; van Der Vliet, HJ, 2000) |
| "Rapid and accurate diagnosis of acute promyelocytic leukemia (APL) is essential for management of the disease, as all-trans retinoic acid (ATRA) therapy only induces complete remission in patients whose leukemic cells harbor a t(15;17) translocation, resulting in promyelocytic-retinoic acid receptor alpha (PML-RAR alpha) fusion transcripts." | ( Gau, JP; Lin, TH; Yang, YS; Young, JH, 2000) |
| "He was diagnosed as having acute promyelocytic leukemia, and treated with all-trans retinoic acid." | ( Kariya, T; Shionoiri, C; Yoneyama, A, 2000) |
| "To study hemostasis in ATRA treatment of acute promyelocytic leukemia (APL)." | ( Cherepanova, VV; Kolupaeva, OR; Kostin, AI; Kudriavtseva, AV; Medvedeva, NA; Tarasova, LN, 2000) |
| "We present a case of acute promyelocytic leukemia who was treated with all-transretinoic acid (ATRA), daunomycin, cytarabine and a short course of dexamethasone." | ( Abhyankar, D; Advani, S; Kapoor, B; Menon, H; Nair, R, 2000) |
| "Complete remission of acute promyelocytic leukemia can be obtained by treating patients with all-trans retinoic acid, and PML-RARalpha plays a major role in mediating retinoic acid effects in leukemia cells." | ( Cavé-Riant, F; Cayre, YE; Di Gioia, Y; Dmowski, S; Eliason, S; Kamens, J; Koretzky, G; Lutz, PG; Moog-Lutz, C; Peterson, EJ; Singer, A, 2001) |
| "Approximately 20%-30% of patients with acute promyelocytic leukemia (APL) who are treated with the current standard all-trans retinoic acid and anthracycline-based chemotherapy regimen suffer relapse." | ( Rust, DM; Soignet, SL, 2001) |
| "We report the second case of acute promyelocytic leukemia (APL), which developed post-transplant and immunosuppressive treatment, in a 50-year-old male who had undergone a renal transplant." | ( Cuneo, A; Liso, V; Mestice, A; Pannunzio, A; Rocchi, M; Specchia, G; Storlazzi, CT; Surace, C, 2001) |
| "Seventeen cases of acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and combination chemotherapy at Tokyo Metropolitan Komagome Hospital between 1992 and 1999 were reviewed, and divided into 2 karyotype-based cytogenetic groups." | ( Akiyama, H; Kono, N; Matsumura, T; Mizuchi, D; Mori, S; Ohashi, K; Okoshi, Y; Sakamaki, H, 2001) |
| "To analyze in patients with de novo acute promyelocytic leukemia (APL) treated with an ATRA plus anthracyclin-based protocol if the presence of additional cytogenetic aberrations to the t(15;17) influences: 1." | ( Alvarez, Mdel C; Calasanz, MJ; Cervera, J; Díaz-Mediavilla, J; Esteve, J; Ferro, MT; González, M; González-San Miguel, JD; Gutiérrez, NC; Hernández, JM; Luño, E; Martín, G; Martínez-Climent, JA; Odriozola, J; Pérez-Equiza, K; Rayón, C; Ribera, JM; Rivas, C; Sanz, MA; Tormo, M, 2001) |
| "Treatment of NB4 acute promyelocytic leukemia cells with 1,25-dihydroxyvitamin D3 (1,25D3) or analogs 20-epi-22-oxa-24a,26a,27a-trihomo-1alpha,25-dihydroxyvitamin D3, 1,24-dihydroxy-22-ene-24-cyclopropylvitamin D3, 1alpha,25-dihydroxylumisterol3, or 1alpha,25(OH)2-d5-previtamin D3 in combination with TPA induces monocytic differentiation." | ( Berry, DM; Clark, CS; Meckling-Gill, KA, 2002) |
| "I (AL), a preparation of As2O3, in treating acute promyelocytic leukemia (APL)." | ( Hu, N; Hu, X; Ma, L, 1999) |
| "All-trans retinoic acid therapy for acute promyelocytic leukemia, which was initially developed as a differentiation therapy in an experienced-based manner, is currently known to be the first successful oncoprotein-directed therapy." | ( Naoe, T, 2001) |
| "Of 82 patients with acute promyelocytic leukemia (APL) who were treated with all-trans retinoic acid (ATRA), 35 developed leukocytosis and 22 fatal side-effects(15 with retinoic acid syndrome and 7 intracranial bleeding)." | ( Han, Z; Pei, M; Xiao, N; Yang, J, 1999) |
| "Arsenic trioxide is an effective treatment for acute promyelocytic leukemia, but resistance to metalloid salts is found in humans." | ( Garnier-Suillerot, A; Petroutsa, M; Salerno, M, 2002) |
| "The treatment of acute promyelocytic leukemia (APL) is different from other subtypes of acute myelocytic leukemia (AML)." | ( Douer, D, 2000) |
| "We describe a patient with an acute promyelocytic leukemia (APL) previously treated with two courses of cytarabin, idarubicin and all-trans retinoic acid (ATRA), who presented a medullary and meningeal relapse after 8 months of complete remission." | ( Fanin, R; Filì, C; Geromin, A; Patriarca, F; Prosdocimo, S; Sperotto, A, 2002) |
| "A patient with acute myeloid leukemia (AML M3) developed gingival hyperplasia and muscle swelling and tenderness after starting treatment with all- trans retinoic acid." | ( Dabadghao, S; Gupta, RK; Melinkeri, SR, 2002) |
| "Sixty-three cases with acute promyelocytic leukemia (APL) were treated with all-trans retinoic acid (ATRA)." | ( Han, ZP; Lu, HB; Shen, ZS, 2000) |
| "The patient was diagnosed as having acute promyelocytic leukemia and was treated with daily oral administration of all-trans retionic acid (ATRA) (45 mg/m2/day) and cytarabine (160 mg/day, intravenous drip infusion for the initial five days)." | ( Izumi, T; Kirito, K; Komatsu, N; Madoiwa, S; Mimuro, J; Miyoshi, T; Nagai, T; Omine, K; Otsuki, T; Ozawa, K; Sakata, Y, 2002) |
| "Therapy related acute promyelocytic leukemia (ta-APL) is a rare complication of chemotherapy for other malignant tumors." | ( Majumdar, G; Martin, J, 2002) |
| "A case of acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) is reported." | ( Feng, R; Jiang, ZJ; Liu, XL; Meng, FY; Yin, F; Zheng, WY; Zhou, SY, 2003) |
| "Approximately 20-30% of patients with acute promyelocytic leukemia (APL) who are treated with all-trans retinoic acid (ATRA) and an anthracycline develop recurrent disease." | ( Cortes, J; Estey, E; Kantarjian, H; Lazo, G; O'Brien, S; Thomas, D, 2003) |
| "Retinoid therapy for acute promyelocytic leukemia (APL) is one of the major achievements of leukemia research in the last 15 years." | ( Gupta, V; Keating, A; Tabak, D, 2003) |
| "She was diagnosed as having acute promyelocytic leukemia and treated with all-trans retinoic acid (70 mg/body) in combination with daunorubicin and cytosine arabinoside." | ( Itoh, M; Shimada, H; Takao, S; Yago, K, 2003) |
| "With improved treatment of acute promyelocytic leukemia (APL) by all trans retinoic acid (ATRA) combined to anthracycline-aracytin chemotherapy (CT), a larger number of those patients may be at risk of late complications." | ( Bordessoule, D; Chevret, S; Chomienne, C; Degos, L; Desablens, B; Fenaux, P; Ferrant, A; Fey, M; Lobe, I; Mounier, C; Rigal-Huguet, F; Sanz, M; Vekhoff, A, 2003) |
| "We describe a patient with acute promyelocytic leukemia (APL) who developed pulmonary embolism (PE) and thrombotic thrombocytopenic purpura (TTP) during remission induction all-trans retinoic acid (ATRA) therapy." | ( Fujisawa, S; Fujita, H; Hyo, R; Ishigatsubo, Y; Kanamori, H; Koharazawa, H; Takemura, S; Tanaka, M, 2003) |
| "All-trans retinoic acid (ATRA) treatment of the acute promyelocytic leukemia (APL) have subsequently resulted in cell apoptosis, but the molecular mechanism of this effect remains elusive." | ( Aktan, M; Dincol, G; Nagy, B; Ozbek, U; Savli, H; Sirma, S, 2003) |
| "Their use in differentiation therapy of acute promyelocytic leukemia (APL) represents a model concept for reprogramming cancer cells." | ( Bennaceur-Griscelli, A; Delhommeau, F; Dudognon, C; Flexor, M; Lanotte, M; Pendino, F; Sahraoui, T; Ségal-Bendirdjian, E, 2003) |
| "Two patients with acute promyelocytic leukemia (APL) relapsed at 111 and 84 months after achievement of complete remission (CR) induced by a combination of all- trans retinoic acid and chemotherapy." | ( Ferrara, F; Mele, G; Palmieri, S; Pane, F; Pocali, B; Rotoli, B; Selleri, C; Serio, B, 2004) |
| "Front line treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA) and chemotherapy (CHT) results in molecular remission in approximately 95% of patients tested after consolidation." | ( Breccia, M; Damiani, D; Diverio, D; Lo Coco, F; Locatelli, F; Marmont, F; Noguera, NI; Petti, MC; Santoro, A; Vignetti, M; Visani, G, 2004) |
| "A 44-year-old man with relapsed acute promyelocytic leukemia (APL), refractory to all-trans-retinoic acid (ATRA), daunorubicin, and cytosine arabinoside, was treated with arsenic trioxide (ATO)." | ( Aisa, Y; Iguchi, T; Ikeda, Y; Miyamoto, K; Mori, T; Okamoto, S; Shimizu, T; Yokoyama, K, 2004) |
| "Over the recent years, treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA) has become a widely accepted therapeutic regimen and is considered a model of differentiation therapy in malignant diseases." | ( Kiener, PA; Salih, HR, 2004) |
| "A 56-year-old woman with an acute promyelocytic leukemia (APL) developed a severe all-trans-retinoic (ATRA) syndrome on day 17 of treatment." | ( Bañas, H; Burgaleta, C; De Miguel, D; García-Suárez, J; Krsnik, I; Reyes, E, 2004) |
| "Patients with acute promyelocytic leukemia (APML) with the t(11;17) translocation usually respond poorly to all-trans retinoic acid (ATRA) and chemotherapy." | ( Chandy, M; George, B; Poonkuzhali, B; Srivastava, A; Srivastava, VM, 2005) |
| "Most reviews on the state-of-the-art treatment in acute promyelocytic leukemia (APL) have focused mainly on the comparison of therapeutic approaches, including all-trans retinoic acid (ATRA) and chemotherapy." | ( Lo-Coco, F; Sanz, MA; Tallman, MS, 2005) |
| "Treatment of human acute promyelocytic leukemia cells with phorbol 12-myristate 13-acetate (PMA) results in growth arrest and differentiation toward monocytes, which subsequently die by apoptosis." | ( Magnusson, KE; Navakauskiene, R; Pivoriunas, A; Savickiene, J; Treigyte, G, 2004) |
| "We studied acute promyelocytic leukemia (APL) with the t(15;17) translocation that developed after treatment of breast or laryngeal cancer with chemotherapeutic agents that poison topoisomerase II." | ( Adès, L; Blair, IA; Cassinat, B; Chomienne, C; Cross, NC; Felix, CA; Fenaux, P; Grimwade, D; Lafage-Pochitaloff, M; Mason, A; Mistry, AR; Osheroff, N; Parry, A; Peniket, AJ; Reiter, A; Segal, MR; Solomon, E; Walz, C; Whitmarsh, RJ; Wiemels, JL, 2005) |
| "We describe 17 cases of therapy-related acute promyelocytic leukemia (tAPL)." | ( Glassman, AB; Jones, D; Lin, P; Luthra, R; Medeiros, LJ; Valbuena, JR; Yin, CC, 2005) |
| "Relapse of acute promyelocytic leukemia (APL) following all-trans retinoic acid (ATRA) therapy has been associated with the acquisition of mutations in the high-affinity ATRA binding site in PML-RARalpha, but little information is available about the selection dynamics of the mutation-harboring subclones." | ( Bi, W; Ding, W; Gallagher, RE; Kim, SH; Livak, KJ; Sankoorikal, BJ; Schachter-Tokarz, EL; Slack, JL; Willman, CL; Zhou, DC, 2006) |
| "We present a case of therapy-related acute promyelocytic leukemia (t-APL) with a subclone accompanied by karyotype 46, XX, t(9; 22)(q34;q11), t(15 ;17)(q22;11 to approximately 12) at onset." | ( Mochiduki, Y; Muramoto, S, 2005) |
| "A 24-year-old woman with acute promyelocytic leukemia was treated with all-trans retinoic acid (ATRA) as a remission induction therapy." | ( Ando, T; Harima, Y; Matsubara, A; Nomiyama, J; Taguchi, A; Takahashi, T; Takemoto, Y; Tanizawa, Y; Yujiri, T, 2005) |
| "Seventy adults with acute promyelocytic leukemia were studied to clarify the significance of the level and kinetics of minimal residual disease (MRD) over their entire treatment course by realtime quantitative polymerase chain reaction." | ( Cho, SG; Eom, KS; Kim, CC; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS, 2006) |
| "Three cases of acute promyelocytic leukemia (APL) occurred during gefitinib treatment, and these patients' past treatment histories are presented herein." | ( Fujiwara, Y; Hotta, K; Ishimaru, F; Kiura, K; Kubonishi, S; Matsuo, K; Nakajima, H; Niiya, D; Ogino, A; Shinagawa, K; Tabata, M; Tanimoto, M; Uchida, A; Ueoka, H, 2006) |
| "The success of treatment of acute promyelocytic leukemia with All Trans Retinoic Acid (ATRA) and CML with imatinib have lead to increased efforts to identify targets that can be inhibited by small molecules for treatment of hematological malignancies." | ( Ikeda, A; Moore, TB; Sakamoto, KM; Shankar, DB; Tamanoi, F; Watanabe, M, 2006) |
| "In an acute promyelocytic leukemia (APL)-transplantable mouse model, we previously reported the presence of antibodies recognizing PML-RARalpha and RARalpha in the sera of ATRA-treated mice." | ( Andreu-Gallien, J; Bengoufa, D; Charron, D; Chomienne, C; Dombret, H; Fenaux, P; Guillemot, I; Larghero, J; Padua, RA; Pla, M; Pokorna, K; Raffoux, E; Robert, C; Robin, M; Rousselot, P; Schlageter, MH, 2006) |
| "We describe 2 patients with acute promyelocytic leukemia (APL) in whom torsade de pointes (TdP) developed during treatment with arsenic trioxide." | ( Kobayashi, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A; Tobita, T, 2006) |
| "The diagnosis was acute promyelocytic leukemia and the patient was treated with ATRA 45 mg/m2/day per oral starting on day 1 and intravenous idarubicin 10 mg/n2 on day 4, 5 and 6." | ( Leelasiri, A; Mongkolsritrakul, W; Numbenjapol, T; Prayoonwiwat, W; Srisawat, C, 2005) |
| "Although the occurrence of thrombosis in acute promyelocytic leukemia (APL) has been reported during retinoic acid treatment, no studies carried out in large clinical cohorts have specifically addressed this issue." | ( Avvisati, G; Breccia, M; Carmosino, I; Cimino, G; De Propris, MS; Gentilini, F; Guarini, A; Latagliata, R; Lo-Coco, F; Mandelli, F; Petti, MC, 2007) |
| "Arsenic trioxide (ATO) has been used to treat acute promyelocytic leukemia (APL), but the oxidative DNA damage occurring in patients has not been fully elucidated." | ( Emi, N; Kajiguchi, T; Kinoshita, T; Naoe, T; Ninomiya, M; Yamamoto, K, 2006) |
| "This review focuses on the treatment of acute promyelocytic leukemia (APL) in elderly patients and offers recommendations for improving outcomes." | ( Estey, E; Kantarjian, H; Keating, MJ; Tsimberidou, AM, 2006) |
| "We report a male patient with acute promyelocytic leukemia and Behçet's disease who had received long-term treatment with colchicine." | ( Bal, N; Boga, C; Ozdogu, H; Sahin, FI; Yilmaz, Z, 2007) |
| "To determine prognosis of acute promyelocytic leukemia (APL) failing to front-line therapy with all-trans retinoic acid (ATRA) and anthracyclines, outcome of 52 patients (32 M/20 F; age: 37, 3-72) included in PETHEMA trials LPA96 and LPA99 who presented with either molecular failure (MOLrel, n=16) or hematological relapse (HEMrel, n=36) was analyzed." | ( Alvarez, C; Bolufer, P; Brunet, S; Colomer, D; Díaz-Mediavilla, J; Escoda, L; Esteve, J; González San Miguel, JD; González, M; Martín, G; Rivas, C; Rubio, V; Sánchez Godoy, P; Sanz, MA; Sayas, MJ; Tomás, JF; Tormo, M, 2007) |
| "Disease relapse sometimes occurs after acute promyelocytic leukemia (APL) therapy with all-trans retinoic acid (ATRA)." | ( Baudet, A; Bertrand, G; Cassinat, B; Chomienne, C; Commes, T; Manchon, L; Marti, J; Piquemal, D; Quere, R, 2007) |
| "From 20% to 30% of patients with acute promyelocytic leukemia (APL) who are treated with all-trans retinoic acid (ATRA) develop recurrent disease." | ( Aribi, A; Cortes, JE; Estey, EH; Faderl, SH; Garcia-Manero, G; Kantarjian, HM; Koller, CA; Kornblau, SM; Laddie, NM; Thomas, DA, 2007) |
| "Current treatment for acute promyelocytic leukemia (APL) usually includes an induction phase with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy, followed by a consolidation phase of anthracycline-based chemotherapy and maintenance therapy with ATRA with or without low-dose chemotherapy for 1-2 years." | ( Tallman, MS, 2007) |
| "Despite recent advances in the treatment of acute promyelocytic leukemia (APL), early mortality and relapses still occur." | ( Chaubey, R; Dutta, P; Hasan, SK; Kumar, B; Kumar, R; Pillai, LS; Saxena, R; Sazawal, S, 2007) |
| "Arsenic trioxide (ATO) is an effective treatment for acute promyelocytic leukemia (APL) and potentially for human T-cell leukemia virus type I (HTLV-I) associated adult T-cell leukemia/lymphoma (ATL)." | ( Abdallah, M; Bazarbachi, A; Darwiche, N; Dbaibo, GS; de Thé, H; El-Sabban, M; Hermine, O; Kfoury, Y; Kozhaya, L; Nasr, R; Panjarian, S, 2007) |
| "A 55-year-old man with acute promyelocytic leukemia in the first relapse was treated with arsenic trioxide as salvage therapy." | ( Abe, Y; Muta, K; Nakashima, Y; Ohtsuka, R; Sada, E; Tachikawa, Y; Takayanagi, R, 2007) |
| "Treatment of acute promyelocytic leukemia (APL) with a combination of anthracycline-based chemotherapy and all-trans retinoic acid (ATRA) leads to very high rates of complete remission and survival." | ( Mellink, CH; Snijder, S; van der Lelie, H, 2008) |
| "We now demonstrate that treatment of acute promyelocytic leukemia (APL)-derived NB4 cells with ATRA results in dissociation of the translational repressor 4E-BP1 from the eukaryotic initiation factor eIF4E, and subsequent formation of eIF4G-eIF4E complexes." | ( Dolniak, B; Hay, N; Kalvakolanu, DV; Kannan-Thulasiraman, P; Kaur, S; Platanias, LC; Sassano, A, 2008) |
| "We also show that treatment of acute promyelocytic leukemia cells with ATO resulted in induction of phosphorylation and activation of Chk2 and p38 MAPK, which are required for ATO-induced apoptosis." | ( Hazaka, Y; Kondo, T; Minami, Y; Onishi, N; Tanaka, Y; Toyoshima, K; Tsukada, J; Tsukuda, Y; Watanabe, Y; Yoda, A, 2008) |
| "All-trans retinoic acid therapy of acute promyelocytic leukemia represents the most successful example of differentiation-induction therapy in clinical oncology." | ( Collins, SJ, 2008) |
| "The standard treatment for acute promyelocytic leukemia (APL) involves differentiation therapy with retinoic acid (RA)." | ( Bunaciu, RP; Reiterer, G; Smith, JL; Yen, A, 2008) |
| "All-trans-retinoic acid (RA) treatment of acute promyelocytic leukemia (APL) cases expressing the t(15;17) product, PML/RARalpha, is a successful example of differentiation therapy." | ( Bissonnette, RP; Blumen, S; Cui, Q; Dmitrovsky, E; Gallagher, R; Kitareewan, S; Lamph, WW; Sekula, D, 2008) |
| "The patient was diagnosed as having acute promyelocytic leukemia microgranular type (M3v) and was therefore administered all-trans retinoic acid (ATRA)." | ( Hisatake, J; Shimozuma, J, 2008) |
| "Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17) translocation is a well-recognized complication of cancer treatment with agents targeting topoisomerase II." | ( Amadori, S; Borlenghi, E; Byl, JA; Cattaneo, C; Cervera, J; Esteve, J; Felix, CA; Grimwade, D; Hasan, SK; La Nasa, G; Ledda, A; Lennard, A; Libura, M; Lo-Coco, F; Mays, AN; Melillo, L; Montefusco, E; Osheroff, N; Ottone, T; Sanz, MA; Satchi, G; Sperr, WR; Stephen, C; Voso, MT, 2008) |
| "To compare survival in Acute Promyelocytic Leukemia (APL) patients treated with or without All-Trans Retinoic Acid (ATRA)." | ( Ahmed, P; Khan, B; Raza, S; Ullah, K, 2008) |
| "The patient was diagnosed with acute promyelocytic leukemia (APL) and was treated with all-trans retinoic acid (ATRA) and idarubicin." | ( Choi, JR; Han, JH; Kim, JK; Kim, JS; Kim, SJ; Lee, EY; Lee, HJ; Lee, KA; Lee, ST; Park, TS; Seok, YM; Song, J, 2009) |
| "In the acute promyelocytic leukemia (APL) bearing the t(15;17), all-trans-retinoic acid (ATRA) treatment induces granulocytic maturation and complete remission of leukemia." | ( Ballarino, M; Bozzoni, I; De Marchis, ML; Fatica, A; Puzzolo, MC; Salvatori, B, 2009) |
| "A patient with acute promyelocytic leukemia(APL)treated with all-trans retinoic acid(ATRA)and chemotherapy for remission induction developed marked thrombocytosis after bone marrow recovery." | ( Kondo, M; Nakabayashi, Y; Shinohara, K; Sugiyama, A; Tominaga, T, 2009) |
| "Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17)(q22;q21) involving the PML and RARA genes is associated with exposure to agents targeting topoisomerase II (topoII), particularly mitoxantrone and epirubicin." | ( Byl, JA; Chang, C; Corser, R; Felix, CA; Grimwade, D; Hasan, SK; Hoyle, C; Lo-Coco, F; Mays, AN; Osheroff, N; Parker, AN; Peniket, A; Saravanamuttu, K; Solomon, E; Wiemels, JL; Xiao, Y, 2010) |
| "There are very limited data on childhood acute promyelocytic leukemia (APL), especially childhood APL treated with arsenic trioxide (As(2)O(3))." | ( Chen, XJ; Chen, YM; Wang, JX; Wang, SC; Yang, WY; Zhang, L; Zhu, XF; Zou, Y, 2009) |
| "He was diagnosed with therapy-related acute promyelocytic leukemia (APL), and treated with all trans-retinoic acid (ATRA)." | ( Kawasaki, Y; Nakazora, T; Shinohara, K; Suzukawa, M; Tominaga, T, 2010) |
| "The results of treatment of acute promyelocytic leukemia, when combination ATRA + chemotherapy is used in induction and maintainance therapy and risk adapted strategy applied in consolidation, improved at present time." | ( Al Sabti, F; Czako, B; Demeckova, E; Demitrovicova, L; Greksak, R; Kotoucek, P; Mego, M; Mikuskova, E; Mistrik, M; Oravcova, I; Richterova, K, 2010) |
| "Treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid and/or arsenic trioxide represents a paradigm in targeted cancer therapy because these drugs cause clinical remission by affecting the stability of the fusion oncoprotein promyelocytic leukemia (PML)/retinoic acid receptor alpha (RARA)." | ( Bjørås, M; Bøe, SO; Isakson, P; Simonsen, A, 2010) |
| "Treatment of acute promyelocytic leukemia (APL) with all-trans-retinoic acid (ATRA) results in terminal differentiation of leukemic cells toward neutrophil granulocytes." | ( Balajthy, Z; Csomós, K; Fésüs, L; Német, I, 2010) |
| "Patients with therapy-related acute promyelocytic leukemia (t-APL) have been commonly exposed to topoisomerase inhibitors and may potentially benefit from induction regimens omitting anthracyclines." | ( Cortes, J; Dayyani, F; Faderl, S; Garcia-Manero, G; Jones, D; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F, 2011) |
| "More effective treatments for acute promyelocytic leukemia (APL) are needed." | ( Bomberger, JM; Chinyengetere, F; Demidenko, E; Dmitrovsky, E; Dolinko, AV; Freemantle, S; Galimberti, F; Gallagher, R; Guo, Y; Liu, X; Ma, T; Sekula, D; Stanton, B; Zhou, DC, 2010) |
| "We report a case of chemotherapy-related acute promyelocytic leukemia (APL) following therapy with VP-16/etoposide for EBV-associated hemophagocytic lymphohistiocytosis (HLH)." | ( Ozdemirli, M; Sathiyamoorthy, S; Shad, A, 2011) |
| "Although standard first line treatment of acute promyelocytic leukemia is All trans retinoic acid (ATRA) and chemotherapy, some patients relapse and need a second line of treatment." | ( Alimoghaddam, K; Ghaffari, H; Ghavamzadeh, A; Hosseini, R; Iravani, M; Jahani, M; Jalili, M; Mousavi, A; Rostami, S, 2011) |
| "In a model of acute promyelocytic leukemia (APL) derived from hCG-PML-RARα transgenic mice, we demonstrated that α-TOS is as effective as arsenic trioxide or all-trans retinoic acid, the current gold standards of therapy." | ( Abreu e Lima, RS; Curti, C; de Thé, H; dos Santos, GA; Falcão, RP; Gimenes-Teixeira, HL; Lima, AS; Lucena-Araujo, AR; Nasr, R; Pandolfi, PP; Pestana, CR; Rego, EM; Rodrigues, FP; Santana-Lemos, BA; Scheucher, PS; Thomé, CH; Uyemura, SA, 2012) |
| "Initial therapy for patients with acute promyelocytic leukemia most often involves the combination of all-trans-retinoic acid with anthracycline-based chemotherapy." | ( Ayling, J; Bradstock, K; Brighton, T; Browett, P; Cannell, P; Catalano, A; Catalano, J; Chong, L; Collins, M; Deveridge, S; Di Iulio, J; Grigg, A; Hertzberg, M; Horvath, N; Iland, H; Reynolds, J; Seymour, J; Springall, F; Supple, S; Taylor, K, 2012) |
| "The treatment of acute promyelocytic leukemia has improved considerably after recognition of the effectiveness of all-trans-retinoic acid (ATRA), anthracycline-based chemotherapy, and arsenic trioxide (ATO)." | ( Bashford, J; Bradstock, K; Browett, P; Catalano, A; Collins, M; Di Iulio, J; Filshie, R; Firkin, F; Grigg, A; Hertzberg, M; Hugman, A; Iland, HJ; Moore, J; Reynolds, J; Seldon, M; Seymour, JF; Supple, SG; Szer, J; Taper, J; Taylor, K; Tiley, C, 2012) |
| "Using an acute promyelocytic leukemia (APL) preclinical model, we show that oncogene-specific PCR (Polymerase Chain Reaction)-based assays allow to evaluate the efficacy of immunotherapy combining all-trans retinoic acid (ATRA) and a DNA-based vaccine targeting the promyelocytic leukemia-retinoic acid receptor alpha (PML-RARα) oncogene." | ( Balitrand, N; Cassinat, B; Chomienne, C; Chopin, M; Le Pogam, C; Padua, RA; Pla, M; Pokorna, K; Reboul, M, 2013) |
| "The prognosis of acute promyelocytic leukemia (APL) in the elderly is poorer than that of younger patients after treatment with all-trans retinoic acid plus chemotherapy, which is the current standard therapy for APL." | ( Fan, S; Han, L; Han, X; Hu, L; Li, J; Li, L; Li, X; Li, Y; Lv, C; Su, Y; Wang, S; Zhang, X; Zhang, Y; Zhang, Z; Zhao, H; Zhao, Y; Zhou, J, 2013) |
| "The current treatment of acute promyelocytic leukemia with arsenic trioxide (ATO) has increased long-lasting complete remissions; however, a proportion of patients continues to die eventually as a result of disease recurrence." | ( Alimoghaddam, K; Bashash, D; Ghaffari, SH; Ghavamzadeh, A; Hassani, S; Hezave, K; Kazerani, M; Rostami, M; Zaker, F, 2013) |
| "The refractoriness of acute promyelocytic leukemia (APL) with t(11;17)(q23;q21) to all-trans retinoic acid (ATRA)-based therapy concerns clinicians and intrigues basic researchers." | ( Ablain, J; Chen, LJ; Chen, SJ; Chen, Z; de Thé, H; Dong, Y; Gao, L; Hu, JP; Jiao, B; Liu, P; Ren, RB; Ren, ZH; Shi, JY; Shi, L, 2013) |
| "The clinical outcomes of acute promyelocytic leukemia (APL) have improved greatly, but treatment failure still occurs." | ( Bae, SH; Hyun, MS; Jang, DY; Jang, JH; Joo, YD; Jung, CW; Kim, DH; Kim, DY; Kim, H; Kim, K; Kim, MK; Lee, JH; Lee, KH; Lee, SJ; Lee, SM; Lee, WS; Park, JH; Park, S; Ryoo, HM, 2013) |
| "The optimal treatments for relapsed acute promyelocytic leukemia (APL) remain equivocal." | ( Atsuta, Y; Emi, N; Fujimaki, K; Fujisawa, S; Fujita, H; Kobayashi, Y; Maeda, A; Miyazaki, Y; Naoe, T; Ohtake, S; Ohwada, A; Sunami, K; Takeshita, A; Taniwaki, M; Tsuboi, K; Tsuzuki, M; Yanada, M, 2013) |
| "Reports about patients with acute promyelocytic leukemia from the Middle East are few; in this study we are reporting our single center experience of treating 29 patients over 6years." | ( Abdelmoety, D; Elemam, O, 2013) |
| "While all-trans retinoic acid (ATRA) treatment in acute promyelocytic leukemia (APL) has been the paradigm of targeted therapy for oncogenic transcription factors, the underlying mechanisms remain largely unknown, and a significant number of patients still relapse and become ATRA resistant." | ( Arteaga, MF; Christensen, J; Dong, S; Helin, K; Kogan, SC; Mikesch, JH; Qiu, J; So, CW, 2013) |
| "Although arsenic is effective in the treatment of acute promyelocytic leukemia (APL), as a well-known environmental toxicant, the side effects of arsenic treatment and arsenic methylation metabolism of the patients are rarely reported." | ( Liu, Z; Sun, G; Wang, F; Wang, H; Wang, Y; Xi, S; Xu, Y; Yang, Y; Zheng, Q; Zheng, Y, 2013) |
| "The standard clinical management of acute promyelocytic leukemia (APL) is differentiation induction therapy using RA." | ( Bunaciu, RP; Yen, A, 2013) |
| "The induction mortality for pediatric acute promyelocytic leukemia remains substantial with wide variation in ATRA administration and high rates of resource utilization." | ( Aplenc, R; Fisher, BT; Gregory, J; Huang, YS; Kavcic, M; Li, Y; Seif, AE; Singh, S; Walker, D, 2014) |
| "This is the first report describing acute promyelocytic leukemia after administration of (89)Sr, to our knowledge, and with an atypical onset and progression." | ( Aotsuka, N; Masuda, S; Matsuura, Y; Utsu, Y; Wakita, H, 2013) |
| "It is a useful pharmacological agent in acute promyelocytic leukemia (APL) treatment, especially the form that is resistant to conventional chemotherapy with all-trans retinoic acid (ATRA)." | ( Hoffman, E; Mielicki, WP, 2013) |
| "Therapy-related acute promyelocytic leukemia (t-APL) has been increasingly reported after exposure to cytotoxic and/or immunosuppressive agents given for prior malignancies or autoimmune diseases." | ( Hasan, SK; Lo-Coco, F; Montesinos, P; Sanz, MA, 2013) |
| "Two female Caucasian acute promyelocytic leukemia patients aged 46 and 56 years developed delirium during their induction treatment with all-trans retinoic acid and idarubicin." | ( Ambrosio, M; Cavallari, M; Cibien, F; Cuneo, A; Daghia, G; Formigaro, L; Lista, E; Martinelli, S; Pizzolato, M; Rigolin, GM; Sofritti, O, 2013) |
| "We suggest that patients with acute promyelocytic leukemia eligible to intensive chemotherapy should be carefully evaluated by a multisciplinary team including psychiatrists in order to early recognize symptoms of delirium and avoid inadequate treatments." | ( Ambrosio, M; Cavallari, M; Cibien, F; Cuneo, A; Daghia, G; Formigaro, L; Lista, E; Martinelli, S; Pizzolato, M; Rigolin, GM; Sofritti, O, 2013) |
| "During last decades acute promyelocytic leukemia, once considered the deadly disease, has evolved to the most treatable of all subtypes of acute myeloid leukemias." | ( Macheta, A; Podhorecka, M, 2013) |
| "The human acute promyelocytic leukemia cell NB4 was treated with different concentrations (0, 1." | ( Dai, JQ; Gao, F; Li, G; Li, GC; Liu, X; Mu, J; Ren, JJ; Song, YP; Wang, H; Wang, L; Wang, QX; Xie, J; Zhang, XB; Zhang, YJ; Zhou, NC, 2015) |
| "A 57-year-old man with acute promyelocytic leukemia was undergoing induction therapy with ATRA and developed episodic seizures with altered consciousness on the 14(th) day and then CAVB followed by cardiac arrest on the 15(th) day." | ( Shih, CH; Wu, HB, 2015) |
| "While acute promyelocytic leukemia (APL) patients are highly responsive to retinoic acid (RA) therapy, kinase inhibitors have been gaining momentum as co-treatments with RA for non-APL acute myeloid leukemia (AML) differentiation therapies, especially as a means to treat relapsed or refractory AML patients." | ( Bunaciu, RP; Jensen, HA; Varner, JD; Yen, A, 2015) |
| "Reports of patients with secondary acute promyelocytic leukemia (APL) have increased in recent years, particularly for those who received treatment with mitoxantrone, and retrospective studies have suggested that their characteristics and outcomes were similar to those of patients with de novo APL." | ( Adès, L; Beaumont, M; Bordessoule, D; Braun, T; Cereja, S; Chevret, S; Chomienne, C; Degos, L; Detourmignies, L; Dombret, H; Fenaux, P; Guerci, A; Lamy, T; Pigneux, A; Poiré, X; Raffoux, E; Recher, C; Spertini, O; Thomas, X; Tournilhac, O, 2015) |
| "We describe an 81-year-old relapsed acute promyelocytic leukemia hemodialysis-dependent patient with a pre-existing cardiac condition who was treated with 10 mg arsenic trioxide three times weekly after dialysis." | ( Eyler, R; Moeller, J; Patel, K; Perreault, S; Pham, T; Podoltsev, N; Russell, K, 2016) |
| "Human acute promyelocytic leukemia NB4 cells were treated either by ATRA or by ATRA plus TNF-α." | ( Gao, Y; Li, M; Wang, C; Yang, H; Yao, Z, 2015) |
| "Prognostic factors for patients with acute promyelocytic leukemia (APL) treated in the context of arsenic trioxide (ATO)-based frontline regimes have not been established clearly." | ( Huang, J; Jin, J; Lou, Y; Ma, Y; Mai, W; Mao, L; Meng, H; Ni, W; Pan, H; Qian, W; Suo, S; Tong, H; Wang, Y; Wei, J; Yu, W, 2015) |
| "G0S2 is strongly induced in acute promyelocytic leukemia (APL) cells in response to all trans retinoic acid (ATRA) and we show that inhibition of ATGL in these cells by G0S2 is required for efficacy of ATRA treatment." | ( El-Assaad, W; Gamache, I; Teodoro, JG; Zagani, R, 2015) |
| "Despite major advances in the treatment of acute promyelocytic leukemia (APL), high-risk APL still poses unique challenges." | ( Altman, JK; Norsworthy, KJ, 2016) |
| "9 treatments for acute promyelocytic leukemia (APL) have been compared in many randomized controlled trials (RCT)." | ( Cai, Y; Chen, W; Du, X; Huang, J; Lou, J; Sun, M; Wang, Z; Zhang, Q, 2016) |
| "Recently, studies in adults with acute promyelocytic leukemia (APL) showed high cure rates in low-risk patients treated with all-trans retinoid acid (ATRA) and arsenic trioxide (ATO), while toxicities were significantly reduced compared to the standard treatment with ATRA and chemotherapy." | ( Bochennek, K; Creutzig, U; Dworzak, MN; Faber, J; Flotho, C; Graf, N; Kontny, U; Mueller, JE; Reinhardt, D; Rossig, C; Schmid, I; von Neuhoff, C; von Neuhoff, N; von Stackelberg, A, 2017) |
| "Therapy-related acute promyelocytic leukemia (t-APL) is relatively rare, with limited data on outcome after treatment with arsenic trioxide (ATO) compared to standard intensive chemotherapy (CTX)." | ( Baer, MR; Benner, A; Burnett, AK; Ehninger, G; Elliott, MA; Estey, EH; Gonzales, P; Görner, M; Grimwade, D; Hills, RK; Ho, AD; Kayser, S; Krämer, A; Krzykalla, J; Levis, MJ; Mayer, J; Norsworthy, K; Novak, J; Platzbecker, U; Ráčil, Z; Röllig, C; Russell, NH; Schlenk, RF; Smith, BD; Szotkowski, T; Tallman, MS; Thiede, C; Walter, RB; Westermann, J; Žák, P, 2017) |
| "Treatment outcome in older patients with acute promyelocytic leukemia (APL) is lower compared with younger patients, mainly because of a higher induction death rate and postremission non-relapse mortality (NRM)." | ( Amutio, ME; Arias, J; Arnan, M; Benavente, C; Bernal, T; Brunet, S; De la Serna, J; Escoda, L; Esteve, J; Gil, C; González-Campos, J; Holowiecka, A; Lowënberg, B; Martínez-Cuadrón, D; Montesinos, P; Negri, S; Pérez-Encinas, M; Ribera, JM; Rubio, V; Salamero, O; Sanz, MA; Vellenga, E, 2018) |
| "Although treatment of acute promyelocytic leukemia (APL) has evolved dramatically during the past decades, especially with the introduction of all-trans retinoic acid, risk stratification remains an important issue." | ( Altmann, H; Doll, S; Ehninger, G; Hecht, A; Hiddemann, W; Hofmann, WK; Lengfelder, E; Nolte, F; Nowak, D; Platzbecker, U; Röllig, C; Spiekermann, K; Weiß, C, 2017) |
| "The prognosis of acute promyelocytic leukemia (APL) has been improved by the combination of all-trans retinoic acid (ATRA) with chemotherapy." | ( Hashida, R; Karigane, D; Kato, J; Mitsuhashi, T; Mori, T; Murata, M; Nakazato, T; Okamoto, S; Sakurai, M; Ueno, H; Watanuki, S; Yamane, Y, 2018) |
| "At present, acute promyelocytic leukemia (APL) is the most curable form of acute myeloid leukemia and can be treated using all-trans retinoic acid and arsenic trioxide." | ( Chen, M; Gan, LG; Li, LW; Liu, BZ; Liu, L; Shan, ZL; Xiao, CL; Xu, T; Yao, SF; Zhao, Y; Zhong, L, 2018) |
| "The treatment of acute promyelocytic leukemia (APL) has been revolutionized in the past two decades by the advent of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO)." | ( Chen, L; Gong, S; Gulati, ES; Li, D; Liu, X; Wang, H; Wang, M; Xi, J; Xie, M; Zhang, H; Zhang, X, 2018) |
| "Retinoic acid is widely used for the treatment of acute promyelocytic leukemia; however, it has adverse effects on the human organism." | ( Akatov, V; Baburina, Y; Fadeev, R; Kobyakova, M; Krestinina, O; Lomovsky, A, 2018) |
| "The treatment of acute promyelocytic leukemia (APL) has changed significantly in recent years." | ( Creutzig, U; Dworzak, M; Rasche, M; Reinhardt, D; von Neuhoff, N, 2018) |
| "The treatment of acute promyelocytic leukemia (APL) has evolved rapidly in the past two decades after the introduction of highly active drugs, including tretinoin (all- trans-retinoic acid) and arsenic trioxide." | ( Anderson, J; Christ, TN; Churpek, JE; Curran, E; Godley, LA; Larson, RA; Liu, H; Odenike, T; Osman, AEG; Stock, W; Thirman, MJ, 2018) |
| "Despite advances in the treatment of acute promyelocytic leukemia (APL) with all-trans-retinoic acid (ATRA), its underlying mechanism has not been fully elucidated." | ( Chen, S; Fang, C; Hu, Y; Lai, J; Li, Y; Wu, Y; Yu, X; Zeng, C; Zeng, Y, 2019) |
| "Increasingly, acute promyelocytic leukemia (APL) is treated with a combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO)." | ( Batista, DA; Borowitz, MJ; Burns, KH; Duffield, AS; Gocke, CD; Miller, KP; Pratz, K; Venkataraman, G, 2019) |
| "While acute promyelocytic leukemia has a good prognosis with all-trans retinoic acid (ATRA) treatment, ATRA resistance is a major obstacle." | ( Gritsman, K; Peeke, SZ, 2019) |
| "We report here an 11-year-old boy with acute promyelocytic leukemia who developed ATRA-induced PTC during leukemia treatment." | ( Matsumoto, K; Miyazaki, O; Okamoto, R; Shirai, R; Tomizawa, D, 2020) |
| "Early death (ED) is the main cause of acute promyelocytic leukemia (APL) treatment failure, and the ED rate is higher for elderly patients than that for young ones." | ( Cao, F; Fu, J; Hou, J; Hou, W; Jin, B; Li, H; Lu, M; Tian, X; Wang, Y; Yang, H; Zhang, Y; Zhou, J, 2020) |
| "Arsenic trioxide is the first-line treatment for acute promyelocytic leukemia (APL); however, abnormalities of ventricular repolarization and QT interval prolongation are the most common adverse effects." | ( Li, D; Que, Y; Sun, Y; Wang, L; Yang, X; Zhu, H, 2020) |
| "Abstract Among myeloid leukemias, the acute promyelocytic leukemia (APL) was found to be specifically sensitive to all-trans retinoic acid (ATRA), almost all APL patients respond to ATRA therapy." | ( Liu, WJ; Niu, YN, 2019) |
| "The standard-of-care for patients with acute promyelocytic leukemia (APL) relapsing after upfront arsenic trioxide (ATO) therapy is not defined." | ( Abraham, A; Alex, AA; Balasubramanian, P; Balasundaram, N; David, S; Devasia, A; Ganesan, S; George, B; Janet, NB; Jeyaseelan, L; Korula, A; Kulkarni, U; Mathews, V; Palani, H; Thenmozhi, M; Venkatraman, A, 2020) |
| "In vivo, the acute promyelocytic leukemia was greatly alleviated in the PDT-PAO-F16 treated group in APL mice model." | ( Fan, XY; Hu, YJ; Jiang, FL; Liu, Y; Liu, YJ; Xia, YZ; Zhang, DD; Zhou, FL, 2020) |
| "The patient was diagnosed with acute promyelocytic leukemia (APL) with PML-RARA and was treated using all-trans retinoic acid (ATRA)." | ( Arai, A; Isobe, Y; Kato, M; Matsunawa, M; Miura, I; Saiki, Y; Sakai, H; Tomita, N; Uchida, A; Uemura, Y, 2020) |
| "For example, the acute promyelocytic leukemia (APL) may be treated with arsenic trioxide." | ( Bo, P; Fu, X; Guo, S; Kuang, T; Li, L; Liu, S; Xiang, X; Xie, X; Zhang, Y, 2020) |
| "A patient suffering from acute promyelocytic leukemia (APL) was referred to the dental department before introduction of chemotherapy by all-trans retinoic acid and arsenic trioxide (ATO)." | ( Bellot, A; Chauvelot, J; Clerc, S; Delaitre, B; Derache, A; Kichenbrand, C; Phulpin, B, 2020) |
| "NB4 cell, the human acute promyelocytic leukemia (APL) cell line, was treated with various concentrations of arsenic trioxide (ATO) to induce apoptosis, measured by staining with 7-amino-actinomycin D (7-AAD) by flow cytometry." | ( Ahn, JY; Huh, J; Lee, KE; Mun, YC; Nam, EM; Rhee, SG; Seong, CM; Woo, HA; Yoo, ES, 2020) |
| "Although majority of acute promyelocytic leukemia (APL) patients achieve complete remission after the standard treatment, 5-10% of patients are shown to relapse or develop resistance to treatment." | ( Navakauskienė, R; Valiulienė, G; Vitkevičienė, A, 2020) |
| "The notable subsets of AML include acute promyelocytic leukemia (APL), core-binding factor AML (CBF-AML), AML in younger patients fit for intensive chemotherapy, and AML in older/unfit patients (usually at the age cutoff of 60-70 years)." | ( DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA, 2021) |
| "Arsenic trioxide (ATO) treats Acute Promyelocytic Leukemia (APL)." | ( Allen, S; Budman, D; Calabro, A; Devoe, C; Dhingra, R; Ghiuzeli, CM; Saunders, J; Stýblo, M, 2022) |
| "A 36-year-old female being treated for acute promyelocytic leukemia presented with rapidly worsening acute on chronic hip pain requiring increasing opioid requriements." | ( Akhtari, M; Cao, H; Hino, C; Ran-Castillo, D; Silvestre, J, 2022) |
| "Beyond RA resistance and acute promyelocytic leukemia context, our study also demonstrates the power of single-cell multiomics to identify, characterize, and clear therapy-resistant cells." | ( Birnbaum, D; Carbuccia, N; Duprez, E; Haboub, L; Hérault, L; Iwama, A; Koide, S; Kuribayashi, W; Mazuel, A; N'Guyen, L; Nakajima-Takagi, Y; Oshima, M; Platet, N; Poplineau, M; Vernerey, J, 2022) |
| "A case of acute promyelocytic leukemia with PLZF / RARa rearrangement reported in this article was treated with induction chemotherapy with arsenic trioxide combined with a new anthracycline (idarubicin) cytotoxic chemotherapy." | ( Duan, X; Liu, B; Yang, M, 2023) |
| "And it was applied to treat acute promyelocytic leukemia (APL) since the 1970s in China." | ( Chen, J; Chen, S; Luo, H; Wang, S; Wu, W, 2023) |